Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study

Manali Kamdar, Julio Chavez, Adam Olszewski, Sarit Assouline, Izidore S. Lossos, Catherine Diefenbach, Dipenkumar Modi, Waleed Sabry, Seema Naik, Amitkumar Mehta, Sneha Makadia, Song Pham, Elicia Peneul, Hao Wu, Wahib S. Ead, Iris To, Dennis J. Houston, Connie Lee Batlevi, Elizabeth Budde

Blood (2025) 146 (Supplement 1): 3735.

https://doi.org/10.1182/blood-2025-3735

Published: 2025

Journal Articles

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe-101 study

Romain Guieze, Annamaria Frustaci, Chan Cheah, John Seymour, Dok Hyun Yoon, Irina Mocanu, Eric Mou, Pier Luigi Zinzani, Amitkumar Mehta, Constantine Tam, Judith Trotman, Yanan Zhang, Linlin Xu, Kunthel By, Amber Lussier, Shannon Fabre, Daniel Persky, Ranjana Advani

Blood (2025) 146 (Supplement 1): 3584.

https://doi.org/10.1182/blood-2025-3584

Published: 2025

Journal Articles

A phase I dose-finding study of mogamulizumab in combination with brentuximab vedotin in previously treated mycosis fungoides and Sézary syndrome

Lauren Shea, Lauren Hughey, Shantyle Kelly, Helen Obaro, Mayur Narkhede, Aditi Saha, Gaurav Goyal, Staci Shea, Heather Dillon, Paige Batson, Craig Elmets, Amitkumar Mehta

Blood (2025) 146 (Supplement 1): 7164.

https://doi.org/10.1182/blood-2025-7164

Published: 2025

Journal Articles

Siltuximab versus tocilizumab for the management of CAR T-cell associated cytokine release syndrome

Sean Patrick Bliven, Lauren Shea, Aditi Saha, Smith Giri, Susan Bal, Antonio Di Stasi, Amitkumar Mehta, Mayur Narkhede

Blood (2025) 146 (Supplement 1): 5919.

https://doi.org/10.1182/blood-2025-5919

Published: 2025

Journal Articles

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study

Blood blood.2025028848.

https://doi.org/10.1182/blood.2025028848

Published: 2025

Journal Articles

Efficacy and Safety of TAK-007, Cord Blood-Derived CD19 CAR-NK Cells, in Adult Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

Justin M. Darrah, Indumathy Varadarajan, Amitkumar Mehta, Jennifer N. Saultz, Matthew McKinney, Monalisa Ghosh, Usama Gergis, Girish Bende, Siddha Kasar, Bradley Hupf, Sharon Chen, Leopold Sellner, Reem Karmali

Blood (2024) 144 (Supplement 1): 95.

https://doi.org/10.1182/blood-2024-194807

Published: 2024

Journal Articles

Phase 2 Trial of Siltuximab for the Treatment of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Related to CAR-T Cell Therapy

Mayur S. Narkhede, Antonio Di Stasi, Lauren Kelly Shea, Susan Bal, Gayathri Ravi, Gaurav Goyal, Pamela Hardwick, Smith Giri, Donna Salzman, Ravi Bhatia, Luciano J. Costa, Amitkumar Mehta

Blood (2024) 144 (Supplement 1): 3449.

https://doi.org/10.1182/blood-2024-205205

Published: 2024

Journal Articles

Communicating with Patients While Navigating the New Landscape of Diffuse Large B-Cell Lymphoma (DLBCL)

Lilly Meier, Elizabeth Budde, Liffy Indu Cherian, Matthew Matasar, Amitkumar Mehta, Nilanjan Ghosh, Ashley Lile, Elana Plotkin, Nicole A Colwell, Molly Kisiel

Blood (2024) 144 (Supplement 1): 7945.

https://doi.org/10.1182/blood-2024-194129

Published: 2024

Journal Articles

Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Primary Analysis of a Phase Ib/II Study

Blood (2023) 142 (Supplement 1): 613.

https://doi.org/10.1182/blood-2023-174209

Published: 2023

Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001 Study

Maria Lia Palomba, Tanya Siddiqi, Leo I. Gordon, Manali Kamdar, Matthew A Lunning, Alexandre V Hirayama, Jeremy S. Abramson, Jon E. Arnason, Nilanjan Ghosh, Amitkumar Mehta, Charalambos Andreadis, Scott R. Solomon, Ana Kostic, Ashvin Singh, Ricardo Espinola, Lily Peng, Ken Ogasawara, Amy Chattin, Michael L. Wang

Blood (2023) 142 (Supplement 1): 3505.

https://doi.org/10.1182/blood-2023-178109

Published: 2023

Journal Articles

Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Joseph Maakaron, Adam S. Asch, Leslie L. Popplewell, Graham P. Collins, Ian W. Flinn, Nilanjan Ghosh, Colin Keane, Matthew Ku, Amitkumar Mehta, Mark Roschewski, Carol O'Hear, Xuehan Ren, Bertha Villa, Indu Lal, Sonali M. Smith, Ranjana H. Advani

Blood (2022) 140 (Supplement 1): 3728–3730.

https://doi.org/10.1182/blood-2022-167772

Published: 2022

Journal Articles

Differences in Progression and Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis at Large Urban Medical Centers

Blood (2022) 140 (Supplement 1): 9431–9433.

https://doi.org/10.1182/blood-2022-170921

Published: 2022

Journal Articles

Tafasitamab (TAFA) Plus Lenalidomide (LEN) Prior to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Case Series of 8 Patients

Muthu Veeraputhiran, Amitkumar Mehta, Alvaro J. Alencar, Dipenkumar Modi, Timothy J. Voorhees, Mayur Narkhede

Blood (2022) 140 (Supplement 1): 12089–12091.

https://doi.org/10.1182/blood-2022-158595

Published: 2022

Journal Articles

Myosteatosis As a Predictor of Toxicity Among Older Adults with DLBCL Receiving CHOP-Based Regimens

Star Ye, Christian Harmon, Nadia Anabtawi, Clare Ubersax, Abigail Tucker, Gaurav Goyal, Lauren Shea, Mayur Narkhede, Amitkumar Mehta, Purnima Singh, Grant Williams, Smita Bhatia, Smith Giri

Blood (2022) 140 (Supplement 1): 3779–3780.

https://doi.org/10.1182/blood-2022-163653

Published: 2022

Journal Articles

Characteristics of Patients with Observation As Initial Treatment Strategy in Mantle Cell Lymphoma

Mayur Narkhede, Lauren Shea, Gaurav Goyal, Amitkumar Mehta

Blood (2022) 140 (Supplement 1): 9358–9360.

https://doi.org/10.1182/blood-2022-164670

Published: 2022

Journal Articles

Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies

Amitkumar Mehta, Umar Farooq, Andy Chen, Joseph P. McGuirk, Thomas Ly, Lilly Wong, Sarah Cooley, Bahram Valamehr, Rebecca Elstrom, Yu-Waye Chu, Jae H. Park

Blood (2022) 140 (Supplement 1): 4577–4578.

https://doi.org/10.1182/blood-2022-167194

Published: 2022

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study

Blood (2022) 140 (Supplement 1): 6623–6626.

https://doi.org/10.1182/blood-2022-157761

Published: 2022

Journal Articles

Trial in Progress: AB-101, an Allogeneic, Non-Engineered, Cord Blood-Derived Natural Killer (NK) Cell Therapy, As Monotherapy or in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Rashmi Khanal, Jennifer N. Saultz, Umar Farooq, Sunita Nathan, Amitkumar Mehta, Ayad Hamdan, Lawrence E. Morris, Jr., Houston Holmes, Lauren C. Pinter-Brown, John K.C. Lim, Amanda Conerty, Heather Raymon, Peter Flynn, Anita G. Seto, Joseph J. Maly

Blood (2022) 140 (Supplement 1): 12742–12743.

https://doi.org/10.1182/blood-2022-159282

Published: 2022

Journal Articles

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204)

Tycel Phillips, Abraham Avigdor, Ronit Gurion, Caterina Patti, Paolo Corradini, Monica Tani, Amitkumar Mehta, Izidore S. Lossos, Pier Luigi Luigi Zinzani, Catherine Thieblemont, Wojciech Jurczak, Fred Zheng, Erica Rappold, Wanying Zhao, Peter Johnson

Blood (2021) 138 (Supplement 1): 44.

https://doi.org/10.1182/blood-2021-147778

Published: 2021

Journal Articles

No Difference in Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis

Pamela Allen, Subir Goyal, Irl Brian Greenwell, Jane Scribner, Sunil Rangarajan, Amitkumar Mehta, Colin Burke O'Leary, Tim Niyogusaba, Auris Huen, Jeffrey M. Switchenko, Erica Shantha Tarabadkar, Amy Ayers, Shalini Krishnasamy, Pierluigi Porcu, Tarsheen Sethi, Swaminathan P Iyer, Mary Jo Lechowicz

Blood (2021) 138 (Supplement 1): 2441.

https://doi.org/10.1182/blood-2021-151911

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe-101 study

A phase I dose-finding study of mogamulizumab in combination with brentuximab vedotin in previously treated mycosis fungoides and Sézary syndrome

Siltuximab versus tocilizumab for the management of CAR T-cell associated cytokine release syndrome

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study

Efficacy and Safety of TAK-007, Cord Blood-Derived CD19 CAR-NK Cells, in Adult Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

Phase 2 Trial of Siltuximab for the Treatment of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Related to CAR-T Cell Therapy

Communicating with Patients While Navigating the New Landscape of Diffuse Large B-Cell Lymphoma (DLBCL)

Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Primary Analysis of a Phase Ib/II Study

Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001 Study

Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Differences in Progression and Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis at Large Urban Medical Centers

Tafasitamab (TAFA) Plus Lenalidomide (LEN) Prior to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Case Series of 8 Patients

Myosteatosis As a Predictor of Toxicity Among Older Adults with DLBCL Receiving CHOP-Based Regimens

Characteristics of Patients with Observation As Initial Treatment Strategy in Mantle Cell Lymphoma

Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies

Trial in Progress: AB-101, an Allogeneic, Non-Engineered, Cord Blood-Derived Natural Killer (NK) Cell Therapy, As Monotherapy or in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204)

No Difference in Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only